IP Library › Assignment 013386/0851
Patent Assignment
Reel/Frame 013386/0851

Change of Name

Recorded: 2002-10-21 Pages: 10
Assignor
ASTA MEDICA AG
Executed: 2001-11-05
Assignee
VIATRIS GMBH & CO. KG
WEISMULLERSTRASSE 45, FRANKFURT AM MAIN, 60314, GERMANY
Covered Properties (68)
2-Amino-3-Carbethoxyamino-6-(P-Fluoro-Benzylamino)-Pyridine-Maleate
Patent: 4,481,205 →
Application: 06/298,886 →
2-Amino-3-Ethoxycarbonylamino-6-(P-Fluoro-Benzylamino)-Pyridine Gluconate and Pharmaceutical Preparations Containing It
Patent: 4,673,666 →
Application: 06/729,413 →
Process for the Production of 2-Amino-3-Nitro-6-(4-Fluorobenzylamino)- Pyridine
Patent: 4,785,110 →
Application: 06/843,253 →
Process for the Production of 1,2-Dithiolan-3-Pentanoic Acid (Thioctic Acid) and 8-Hydrocarbylthio-6-Oxooctanoic Acid
Patent: 4,966,732 →
Application: 07/073,584 →
Process for Producing Storable Camomile Extracts Rich in Active Substances
Patent: 4,786,497 →
Application: 07/096,211 →
Process for the Production of Camomile Extracts Rich in Flavones
Patent: 4,786,498 →
Application: 07/153,481 →
Azelastine and Its Salts Used to Combat Psoriasis
Patent: 5,110,814 →
Application: 07/458,350 →
Method of Treating Inflammatory Diseases with Pharmaceutical Composition Containing Dihydrolipoic Acid as Active Substance
Patent: 5,084,481 →
Application: 07/476,042 →
Azelastine Containing Medicaments
Patent: 5,164,194 →
Application: 07/551,644 →
Azelastine Embonate and Compositions Which Contain It
Patent: 5,232,919 →
Application: 07/598,742 →
Pharmaceutical Compositions Containing as Active Substance Sulphur- Containing Carboxylic Acids and Their Use in Combating Retroviruses
Patent: 5,334,612 →
Application: 07/610,560 →
Method of Treating Inflammatory Disorders and Psoriasis with Salts of Azelastine
Patent: 5,086,050 →
Application: 07/652,986 →
Camomile Extract Having Antimicrobial Properties, Process for Its Manufacture and Its Use
Patent: 5,244,885 →
Application: 07/820,407 →
Controlled Release Azelastine-Containing Pharmaceutical Compositions
Patent: 5,271,946 →
Application: 07/865,769 →
Pharmaceutical Composition Comprising Flupirtine and Its Use to Combat Parkinson Disorders
Patent: 5,284,861 →
Application: 07/890,730 →
Camomile Oils Having a High Natural Poly-Ynes Content and Process for Their Production
Patent: 5,902,587 →
Application: 07/908,856 →
Novel Pharmaceutically Active 1,2,4-Triamino-Benzene Derivatives, Processes for Their Preparation and Pharmaceutical Compositions Containing Them
Patent: 5,384,330 →
Application: 08/002,458 →
Tablets, Granulates and Pellets with a High Active Substance Content for Highly Concentrated, Solid Dosage Forms of Thioctic Acid
Patent: 5,376,382 →
Application: 08/025,053 →
Rs-Thioctic Acid with Novel Morphology
Patent: 5,455,264 →
Application: 08/134,695 →
Combination Medication Containing Flupirtin and Morphine for the Treatment of Pain and the Prevention of Morphine Dependence
Patent: 5,521,178 →
Application: 08/141,678 →
Stable Formulation of Plant Extract
Patent: 5,389,372 →
Application: 08/149,813 →
Pharmaceutical Dosage Unit for Rectal Administration
Patent: 5,433,958 →
Application: 08/216,840 →
Tablets, Granulates and Pellets with a High Active Substance Content for Highly Concentrated, Solid Dosage Forms
Patent: 5,503,845 →
Application: 08/285,145 →
Preparation for Treating Circulatory Changes
Patent: 5,532,269 →
Application: 08/320,400 →
Method for the Preparation of Hexahydroazepinones and Hexahydoazepinoles
Patent: 5,760,221 →
Application: 08/359,457 →
Use of R-(+)-Alpha-Lipoic Acid, R-(-)Dihydrolipoic Acid and Metabolites in the Form of the Free Acid or Salts or Esters or Amides for the Preparation of Drugs for the Treatment of Diabetes Mellitus as Well as of Its Sequelae
Patent: 5,693,664 →
Application: 08/360,924 →
Tablets with Thioctic Acid of Specific Particle Size
Patent: 5,527,539 →
Application: 08/367,480 →
Combination Medications Containing Alpha-Lipoic Acid and Related Compounds
Patent: 5,569,670 →
Application: 08/404,153 →
Method for the Racemization of Enantiomers of Alpha-Lipoic Acid
Patent: 5,621,117 →
Application: 08/504,557 →
Use of Dl-(+/-)-Alpha-Lipoic Acid, D-(+)- Alpha- Lipoic Acid, L-(-) -Alpha-Lipoic Acid in Reduced or Oxidized Form or Salts for Treating Circulatory Disorders
Patent: 5,650,429 →
Application: 08/554,418 →
A Method of Increasing Viability of Stored Erythrocytes by Addition of Lipoic, Dihydrolipoic, 6,8-Bisnortetralipoic, or Tetranorlipoic Acid
Patent: 5,827,643 →
Application: 08/554,421 →
Nhe Primary and Secondary Neuroprotective Effect of Flupirtine in Neurodegenerative Diseases
Patent: 5,721,258 →
Application: 08/602,742 →
Method of Producing Flowable R,S-Thioctic Acid, R,S-Thioctic Acid and Its Use
Patent: 5,705,192 →
Application: 08/618,790 →
Salts of Azelastine Having Improved Solubility
Patent: 5,859,003 →
Application: 08/691,415 →
(+) and (-)-8-Chloro-6-Sulfonyloxy-Octanoic Acid, Its Derivatives, and Methods for Making
Patent: 5,731,448 →
Application: 08/705,212 →
(+)- and (-)-8-Halogen-6-Hydroxy-Octanoic Acid, Its Salts and Esters, and Process for Making
Patent: 5,869,713 →
Application: 08/705,591 →
Use of 2-4-Amino-4- (4 - Fluorobenzylamino) ( - 1 - Ethoxy - Carbonylaminobenzene for the Prophylaxis and Treatment of the Neurodegenerative Disorders
Patent: 5,852,053 →
Application: 08/736,166 →
Use of Flupirtine for the Prophylaxis and Therapy of Diseases Associated with an Impairment of the Haematopetic Cell System
Patent: 6,034,111 →
Application: 08/744,953 →
Use of Selegiline for the Treatment of Epileptic Disorders
Patent: 5,952,388 →
Application: 08/776,931 →
Production and Use of Salts of 6,8-Bis(Amidiniumthio)-Octanoic Acid
Patent: 5,760,268 →
Application: 08/786,053 →
Pharmaceutical Composition Containing R-Alpha-Lipoic Acid or S-Alpha-Lipoic Acid as Active Ingredient
Patent: 5,728,735 →
Application: 08/794,310 →
Dosage Forms Containing Thiotic Acid or Solid Salts of Thiotic Acid with Improved Release and Bioavailability
Patent: 5,990,152 →
Application: 08/800,239 →
Use of Flupirtine for the Prophylaxis and Therapy of Disorders Which Are Associated with an Unphysiologically High Cell Death Rate
Patent: 6,124,326 →
Application: 08/873,124 →
Use of R-(+)-a-Lipoic Acid and Metabolites in the Form of the Free Acid or Salts or Esters or Amides for the Preparation of Drugs for the Treatment of Diabetes Mellitus as Well as of Its Sequelae
Patent: 5,948,810 →
Application: 08/878,843 →
Method Employing a Stable Preparation Containing Azelastine Hydrochloride
Patent: 6,117,864 →
Application: 08/889,807 →
Multiple Unit Oral Pharmaceutical Formulations
Patent: 5,955,104 →
Application: 08/896,629 →
Use of 4-Amino-4-(4-Fluorobenzylamino)-1-Ethoxy-Carbonylaminobenzene for the Prophylaxis and Treatment of Reduced Cerebral Blood Supply
Patent: 5,849,789 →
Application: 08/937,420 →
Process for the Production of Lipoic Acid
Patent: 6,140,512 →
Application: 08/952,698 →
Novel Modifications of 2-Amino-4-(4-5FLUOROBENZYLAMINO)-1- Ethoxycarbonylaminobenzene, and Processes for Their Preparation
Patent: 5,914,425 →
Application: 09/004,926 →
Thioctic Metabolites and Methods of Use Thereof
Patent: 5,925,668 →
Application: 09/009,770 →
Pharmaceutical Compositions Containing R-a-Lipoic Acid or S-a-Lipoic Acid as Active Ingredient
Patent: 6,271,254 →
Application: 09/017,409 →
Process for the Preparation of Enantiomerically Pure 3-Hydroxyoctanedioic Acid Diesters by Asymmetric Catalytic Hydrogenation
Patent: 6,013,833 →
Application: 09/035,811 →
Production and Use of Salts of 6, 8-Bis (Amidiniumthio) -Octanoic Acid
Patent: 6,013,815 →
Application: 09/040,440 →
Use of Flupirtine the Prophylaxis and Therapy of Diseases Associated with an Impairment of the Haematopoetic Cell System
Patent: 6,034,112 →
Application: 09/061,099 →
Process for the Preparation of Pure Flupirtine Maleate and Its a Modification
Patent: 5,959,115 →
Application: 09/064,790 →
Alpha-Lipoic Acid with Novel Modification
Patent: 5,994,393 →
Application: 09/074,645 →
Camomile Oils Having a High Content of Natural Poly-Ynes and Process for Their Preparation
Patent: 6,300,370 →
Application: 09/095,146 →
Method of Producing Dry Thioctic Acid
Patent: 5,981,767 →
Application: 09/102,758 →
Salts of Azelastine Having Improved Solubility Useful at Providing a Cytoprotective Effect
Patent: 5,998,403 →
Application: 09/123,431 →
Salts of Azelastine Having Improved Solubility Effective at Treating Psoriasis and Providing a Cytopprotective Effect
Patent: 6,017,909 →
Application: 09/136,971 →
(+)- and (-) -8-Halogen-6- Hydroxy-Octanoic Acid Its Salts and Esters and Process for Making
Patent: 5,977,391 →
Application: 09/186,674 →
Effervescent Formulations
Patent: 6,242,002 →
Application: 09/277,393 →
Solid, Rapidly Disintegrating Cetirizine Formulations
Patent: 6,245,353 →
Application: 09/277,403 →
Use of R-(+)-Alpha-Lipoic Acid, R-(-)-Dihydrolipoic Acid and in the Form of the Free Acid or as Salts or Esters or Amides for the Preparation of Drugs for the Treatment of Diabetes Mellitus as Well as Its Sequelae
Patent: 6,117,899 →
Application: 09/285,460 →
Use of Retigabine for the Treatment of Neuropathic Pain
Patent: 6,117,900 →
Application: 09/406,135 →
Process for the Preparation of Enantiomerically Pure 3-Hydroxyoctanedioic Acid Diesters by Asymmetric Catalytic Hydrogenation
Patent: 6,229,042 →
Application: 09/443,049 →
Use of r-(+)-a-lipoic acid, r-(-)-dihydrolipoic acid and mettabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
Patent: 6,284,787 →
Application: 09/628,295 →
Treatment of migraine by administration of a-lipoic acid or derivatives thereof
Patent: 6,251,935 →
Application: 09/638,034 →
Related Assignments (22)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jul 28, 1997
From: ASTA PHARMA AKTIENGESELLSCHAFT
To: ASTA MEDICA AKTIENGESELLSCHAFT
Reel/Frame 008613/0535 →
Assignment of Assignor's Interest Jun 29, 2000
From: DEGUSSA AKTIENGESELLSCHAFT
To: DEGUSSA-HULS AKTIEGESELLSCHAFT
Reel/Frame 010927/0072 →
Assignment of Assignor's Interest Oct 5, 2000
From: DEGUSA-HULS AKTIENGESELLSCHAFT
To: ASTA MEDICA AKTIENGESELLSCHAFT
Reel/Frame 011219/0331 →
Assignment of Assignor's Interest Sep 10, 2002
From: VIATRIS GMBH & CO. KG
To: MEDPOINTE HEALTHCARE, INC.
Reel/Frame 013269/0141 →
Security Interest Oct 8, 2003
From: MEDPOINTE INC.; MCC ACQUISITION SUB CORPORATION; MCC MERGER SUB CORPORATION
To: LEHMAN COMMERCIAL PAPER, INC.
Reel/Frame 014567/0804 →
Assignment of Assignor's Interest Apr 9, 2004
From: VIATRIS GMBH & CO. KG
To: XCEL PHARMACEUTICALS, INC.
Reel/Frame 015190/0450 →
Release of Security Agreement Mar 7, 2005
From: REGIMENT CAPITAL III, L.P.
To: XCEL PHARMACEUTICALS, INC.
Reel/Frame 015732/0626 →
Change of Name Aug 31, 2005
From: ASTA PHARMA AKTIENGESELLSCHAFT
To: ASTA MEDICA AKTIENGESELLSCHAFT
Reel/Frame 016470/0610 →
Corrective Assignment to Correct the Patent Number from 5,232,219 Previously Recorded on Reel 016470 Frame 0610. Assignor(S) Hereby Confirms the Correct Patent Number Is 5,232,919. Sep 1, 2005
From: ASTA PHARMA AKTIENGESELLSCHAFT
To: ASTA MEDICA AKTIENGESELLSCHAFT
Reel/Frame 016480/0246 →
Release of Security Interest May 25, 2006
From: LEHMAN COMMERICAL PAPER INC.
To: MEDPOINTE HEALTHCARE INC.
Reel/Frame 017675/0384 →
Security Agreement Jun 6, 2006
From: MEDPOINTE HEALTHCARE INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 017730/0008 →
Change of Name Apr 4, 2007
From: VIATRIS GMBH & CO. KG
To: MEDA PHARMA GMBH & CO. KG
Reel/Frame 019111/0228 →
Change of Name May 10, 2007
From: VIATRIS GMBH & CO. KG
To: MEDA PHARMA GMBH & CO. KG
Reel/Frame 019280/0347 →
Change of Name Jun 17, 2008
From: XCEL PHARMACEUTICALS, INC.
To: VALEANT PHARMACEUTICALS NORTH AMERICA
Reel/Frame 021109/0099 →
Change of Name Jul 22, 2008
From: MEDPOINTE HEALTHCARE INC.
To: MEDA PHARMACEUTICALS INC.
Reel/Frame 021266/0524 →
Change of Name Aug 12, 2008
From: VIATRIS GMBH & CO. KG
To: MEDA PHARMA GMBH & CO. KG
Reel/Frame 021371/0425 →
Assignment of Assignor's Interest Sep 30, 2008
From: MEDA PHARMA GMBH & CO. KG
To: EVONIK DEGUSSA GMBH
Reel/Frame 021603/0317 →
Security Agreement Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
Patent Security Release Agreement Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 025950/0048 →
Security Agreement Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
Notice of Succession of Agency Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
Release of Security Interest Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →